Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

UBC Medicine Researchers Awarded More Than $39 Million in CIHR Funding

August 17, 2026

[The University of British Columbia] UBC Faculty of Medicine researchers have been awarded more than $39 million in federal funding through the Canadian Institutes of Health Research (CIHR) Project Grant: Spring 2026 competition.

CAR T Cell Therapy beyond Cancer: Current Status, Challenges, and Future Prospects

August 11, 2026

[Signal Transduction and Targeted Therapy] The authors highlight how CAR-based strategies can be adapted across diverse disease settings by redirecting engineered immune responses toward disease-sustaining cellular compartments.

Armored Chimeric Antigen Receptor T-Cell Therapy Targets Antigen-Heterogeneous Glioma

August 11, 2026

[Cancer Research] Through head-to-head in vivo comparisons of potentially synergistic armor combinations, researchers demonstrated that T cells expressing a CAR plus IL12 and the decoy-resistant form of IL18 show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice.

FDA-Approved Fulvestrant-Induced CAR Phase Separation Enables Precise Control of CAR T Antitumor Function

July 20, 2026

[Cell Stem Cell] Researchers developed a drug-inducible phase-separation CAR system utilizing FDA-approved fulvestrant and an engineered estrogen receptor α mutant as the drug-inducible phase-separation module.

Non-Armored GCC-Targeting CAR-T Cell Therapy Demonstrates Significant Efficacy in Patients with Advanced Colorectal Cancer

July 20, 2026

[Clinical Cancer Research] Scientists evaluated the safety, expansion kinetics, and preliminary efficacy of non-armored, nanobody-derived GCC-targeted CAR-T cells in patients with heavily pretreated, metastatic colorectal cancer.

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis

July 20, 2026

[Cancer Research] The authors identified an innate-adaptive circuit in which toll-like receptor (TLR) 9-activated B cells augment CD8⁺ T cell fitness and antitumor activity through CD2-dependent costimulation.

Sleeping Beauty Mutagenesis Identifies BACH2 and Other Regulators of CD8+ T Cell Exhaustion, Persistence In Vivo, and CAR-T Cell Function Under Tumor-Associated Chronic Antigen...

July 20, 2026

[Journal for Immunotherapy of Cancer] Controllable Sleeping Beauty mutagenesis using DiSBey mice provides a novel platform for functional screening of genes that improve T cell phenotypes important for their use as therapies. Researchers highlighted a dose-dependent role of BACH2 in enhancing the function of engineered T cells under conditions of chronic antigenic stimulation.

Hemophagocytic Lymphohistiocytosis-Like Syndrome after CD19-Directed CAR T Cells for B Cell Lymphoma and B Cell Acute Lymphoblastic Leukemia: A LYSA, SFCE, and GRAALL Study...

July 20, 2026

[HemaSphere] Investigators conducted a multicenter retrospective study of patients registered in DESCAR-T who received standard-of-care CD19 CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma or B cell acute lymphoblastic leukemia and fulfilled ASTCT criteria for immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS).

Dual-Targeting LILRB3/LILRB4 CAR-T Cells for the Treatment of Monocytic Acute Myeloid Leukemia

July 20, 2026

[Biochemical Pharmacology] The expression of LILRB3 and LILRB4 was analyzed in monocytic acute myeloid leukemia (AML) patient samples, leukemic stem cell-enriched populations, and AML cell lines, revealing frequent co-expression and suggesting that a dual-targeting approach may provide enhanced therapeutic benefit.

Expression of the Switch Receptor PD1/IL15Rβ in MSLN-CAR-T Cells Overcomes PD1/PDL1 Signaling in Solid Tumors

July 20, 2026

[Scientific Reports] Researchers engineered MSLN-CAR-T cells with a PD1/IL15Rβ switch receptor to convert PD1/PDL1 inhibitory signals into IL15-mediated STAT5 activation, enhancing T cell function.

Long-Term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma

July 20, 2026

[Clinical and Experimental Dermatology] Scientists reported a 60-year-old woman with a 49-year history of severe, treatment-refractory plaque psoriasis who developed complete and sustained disease clearance following autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy for follicular lymphoma.

Gene Expression Profiling of Recipient Immune Cells Induced by 7 × 19 CAR-T Cell Dosing in a Syngeneic Mouse Model

July 20, 2026

[PloS One] CAR-T cells expressing interleukin-7 and CC chemokine ligand 19 were generated to achieve potent antitumor efficacy through the recruitment and proliferation of CAR-T cells and endogenous immune cells.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.